De La Cadena RA, Baglia FA, Johnson CA, Wenk RE, Amernick R, Walsh PN, Colman RW. Blood. 1988 Nov;72(5):1748-54. We have isolated and probed the mechanism of action of two naturally occurring antibodies (Baltimore and Winston-Salem) against factor XI (FXI), that developed in patients congenitally deficient in FXI after replacement therapy. Purification on immobilized protein A and neutralization with monospecific antibodies against [...]
View Post coagulation, factor XI, Factor XIaScott CF, Silver LD, Purdon AD, Colman RW. J Biol Chem. 1985 Sep 5;260(19):10856-63. We have recently demonstrated that human high molecular weight kininogen (HMWK) is a pro-cofactor that is cleaved by kallikrein to yield a two-chain cofactor (HMWKa) and the nanopeptide bradykinin. This proteolysis enhances its association with an activating surface, an event necessary for expression of its [...]
View Post bradykinin, Factor XIa, factor XII, kallikreinWalsh PN, Griffin JH. Blood. 1981 Jan;57(1):106-18. READ HERE: http://bloodjournal.hematologylibrary.org/content/57/1/106.full.pdf
View Post coagulation, factor XI, factor XIISeligsohn U, Osterud B, Brown SF, Griffin JH, Rapaport SI. J Clin Invest. 1979 Oct;64(4):1056-65. Factor VII can be activated, to a molecule giving shorter clotting times with tissue factor, by incubating plasma with kaolin or by clotting plasma. The mechanisms of activation differ. With kaolin, activated Factor XII (XII(a)) was the apparent principal activator. Thus, Factor VII was not [...]
View Post Factor IX, Factor VII, factor XII, kallikrein